Inclusion Criteria:

          -  Parts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III
             (excluding visceral or nodal involvement), and must be refractory to or intolerant of
             established therapies for their condition

          -  Part D only: Patients diagnosed with CLL who are intolerant to, or have disease that
             is relapsed/refractory after, at least two prior therapies

          -  Part E only: Patients with biopsy-proven DLBCL who are intolerant to, or have disease
             that is relapsed/refractory after, at least two prior therapies, including any
             anti-CD20 monoclonal antibody and chemotherapy with curative intent

          -  Part F only: Patients with documented HTLV-1 infection and histologically or
             cytologically proven ATLL of any stage, and who are intolerant to, or have disease
             that is relapsed/refractory after, at least one prior therapy

          -  Females must not be pregnant or lactating. Women of child-bearing potential must use a
             highly effective method of contraception throughout their study participation and for
             at least 6 months following the last dose of study drug.

          -  Males must be surgically sterile, abstinent, or if engaged in sexual relations with a
             female of child-bearing potential, must be willing to use a highly effective method of
             contraception throughout their study participation and for at least 6 months after the
             last dose of study drug.

        Exclusion Criteria:

          -  Evidence of renal or liver dysfunction at screening

          -  Clinically significant anemia, neutropenia or thrombocytopenia at screening

          -  History of bleeding diathesis or coagulopathy

          -  Clinically significant cardiovascular disease, history of myocardial infarction within
             the last 6 months, or evidence of QTc interval prolongation at screening

          -  Serologically positive for HIV; serologically positive for Hepatitis B or Hepatitis C
             with evidence of liver dysfunction or documented liver cirrhosis

          -  Prior malignancies within the past 3 years (with allowance for adequately treated in
             situ carcinoma of the cervix uteri, and basal cell or localized squamous cell
             carcinoma of the skin treated with curative intent)

          -  Use of an investigational small molecule drug during the 30 days prior to screening or
             use of an investigational oligonucleotide or biologic drug during the prior 90 days